Bristol’s New Products Meet Early Launch Expectations
Even So, Currency Changes Lead To Lowered Revenue Guidance
Executive Summary
Sales rose significantly for Reblozyl and for Abecma and Breyanzi, despite manufacturing challenges for the two cell therapies. Newly approved Opdualag and Camzyos are off to encouraging starts.
You may also be interested in...
BMS’s Phase III Reblozyl Trial Hits Mark In First-Line, Lower-Risk Myelodysplastic Syndrome
The drug’s success in the Phase III COMMANDS trial could double its addressable market, though some analysts said durability remains a question.
Dr Reddy’s Debuts Two Revlimid Exclusives As Part Of Complete Launch In US
Dr Reddy’s Laboratories is set to reap the rewards of a significant US generic launch – albeit one with a limited volume caveat decreed by a patent-litigation settlement deal – after it began selling its generic of Bristol Myers Squibb’s multi-billion-dollar blockbuster Revlimid.
US Pharmas Display Defensive Mettle But Headwinds Mount
US big pharma manufacturers generally delivered sales and earnings growth in the second quarter and reaffirmed guidance despite currency headwinds; US drug pricing legislation could present a tipping pressure point.